NO329827B1 - Anvendelse av inhibitorer av IL-18 produksjon og/eller dets virkning ved fremstilling av medikamenter for a hemme metastase av melanom, og anvendelse av en ekspresjonsvektor som koder for en inhibitor for IL-18 produksjon og deller dets virkning ved fremstillingen av medikamenter for a hemme metastase av melanom - Google Patents

Anvendelse av inhibitorer av IL-18 produksjon og/eller dets virkning ved fremstilling av medikamenter for a hemme metastase av melanom, og anvendelse av en ekspresjonsvektor som koder for en inhibitor for IL-18 produksjon og deller dets virkning ved fremstillingen av medikamenter for a hemme metastase av melanom Download PDF

Info

Publication number
NO329827B1
NO329827B1 NO20020153A NO20020153A NO329827B1 NO 329827 B1 NO329827 B1 NO 329827B1 NO 20020153 A NO20020153 A NO 20020153A NO 20020153 A NO20020153 A NO 20020153A NO 329827 B1 NO329827 B1 NO 329827B1
Authority
NO
Norway
Prior art keywords
cells
production
hse
metastasis
inhibitor
Prior art date
Application number
NO20020153A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020153D0 (no
NO20020153L (no
Inventor
Charles Dinarello
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20020153D0 publication Critical patent/NO20020153D0/no
Publication of NO20020153L publication Critical patent/NO20020153L/no
Publication of NO329827B1 publication Critical patent/NO329827B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20020153A 1999-07-22 2002-01-11 Anvendelse av inhibitorer av IL-18 produksjon og/eller dets virkning ved fremstilling av medikamenter for a hemme metastase av melanom, og anvendelse av en ekspresjonsvektor som koder for en inhibitor for IL-18 produksjon og deller dets virkning ved fremstillingen av medikamenter for a hemme metastase av melanom NO329827B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13104799A IL131047A0 (en) 1999-07-22 1999-07-22 Use of il-18 inhibitors
PCT/IL2000/000419 WO2001007480A2 (en) 1999-07-22 2000-07-17 Use of interleukin-18 inhibitors to inhibit tumor metastasis

Publications (3)

Publication Number Publication Date
NO20020153D0 NO20020153D0 (no) 2002-01-11
NO20020153L NO20020153L (no) 2002-03-11
NO329827B1 true NO329827B1 (no) 2011-01-03

Family

ID=11073044

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020153A NO329827B1 (no) 1999-07-22 2002-01-11 Anvendelse av inhibitorer av IL-18 produksjon og/eller dets virkning ved fremstilling av medikamenter for a hemme metastase av melanom, og anvendelse av en ekspresjonsvektor som koder for en inhibitor for IL-18 produksjon og deller dets virkning ved fremstillingen av medikamenter for a hemme metastase av melanom

Country Status (31)

Country Link
US (1) US7741276B2 (2)
EP (1) EP1206274B1 (2)
JP (1) JP4827352B2 (2)
KR (1) KR100682219B1 (2)
CN (1) CN1173736C (2)
AR (1) AR024907A1 (2)
AT (1) ATE363288T1 (2)
AU (1) AU782478B2 (2)
BG (1) BG65800B1 (2)
BR (1) BR0012675A (2)
CA (1) CA2380216C (2)
CY (1) CY1107932T1 (2)
CZ (1) CZ302114B6 (2)
DE (2) DE1206274T1 (2)
DK (1) DK1206274T3 (2)
EA (1) EA005419B1 (2)
EE (1) EE04838B1 (2)
ES (1) ES2186596T3 (2)
HK (1) HK1048248B (2)
HU (1) HU228780B1 (2)
IL (2) IL131047A0 (2)
MX (1) MXPA02000838A (2)
NO (1) NO329827B1 (2)
NZ (1) NZ516535A (2)
PL (1) PL202477B1 (2)
PT (1) PT1206274E (2)
SK (1) SK287522B6 (2)
TR (1) TR200200169T2 (2)
UA (1) UA73745C2 (2)
WO (1) WO2001007480A2 (2)
ZA (1) ZA200200390B (2)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335336B (2) 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
CA2424983A1 (en) 2000-10-11 2002-04-18 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
ES2334773T3 (es) * 2001-05-16 2010-03-16 Yeda Research And Development Co. Ltd. Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis.
RU2225720C1 (ru) * 2002-08-12 2004-03-20 Научно-исследовательский институт онкологии Томского научного центра СО РАМН Средство, повышающее противоопухолевую и антиметастатическую активность циклофосфана
MXPA05003869A (es) * 2002-10-08 2005-06-22 Ares Trading Sa El uso de citocina capaz de enlazarse a la proteina de union a interleucina-18, y de inhibir la actividad de una segunda citocina.
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP2267024B1 (en) 2005-06-03 2012-05-09 Ares Trading S.A. Production of recombinant Il-18 binding protein
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
US9812033B2 (en) * 2013-03-06 2017-11-07 Venkatesh R. Chari Tactile graphic display
PE20251671A1 (es) 2022-03-15 2025-06-30 Compugen Ltd Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer
IL321948A (en) 2023-01-06 2025-09-01 Lassen Therapeutics Inc Anti-IL-18 BP antibodies
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2143748A1 (en) * 1992-09-02 1994-03-17 C. Frank Bennett Oligonucleotide modulation of cell adhesion
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use

Also Published As

Publication number Publication date
MXPA02000838A (es) 2002-07-30
ES2186596T1 (es) 2003-05-16
PT1206274E (pt) 2007-07-06
NO20020153D0 (no) 2002-01-11
DE60035049D1 (de) 2007-07-12
EA005419B1 (ru) 2005-02-24
PL202477B1 (pl) 2009-06-30
CZ302114B6 (cs) 2010-10-20
EP1206274A2 (en) 2002-05-22
WO2001007480A2 (en) 2001-02-01
PL353732A1 (en) 2003-12-01
TR200200169T2 (tr) 2002-06-21
JP4827352B2 (ja) 2011-11-30
HUP0202107A2 (en) 2002-10-28
BRPI0012675B1 (pt) 2001-02-01
AU782478B2 (en) 2005-08-04
ZA200200390B (en) 2003-04-30
IL131047A0 (en) 2001-01-28
IL147675A (en) 2009-05-04
KR100682219B1 (ko) 2007-02-12
DE1206274T1 (de) 2002-11-14
CZ2002195A3 (cs) 2002-06-12
ATE363288T1 (de) 2007-06-15
DK1206274T3 (da) 2007-08-13
EA200200189A1 (ru) 2002-12-26
KR20020027493A (ko) 2002-04-13
SK287522B6 (sk) 2011-01-04
SK882002A3 (en) 2002-07-02
BG65800B1 (bg) 2009-12-31
CA2380216C (en) 2012-01-31
WO2001007480A3 (en) 2001-05-10
US20080003216A1 (en) 2008-01-03
BG106311A (en) 2002-08-30
EE200200032A (et) 2003-02-17
ES2186596T3 (es) 2007-11-16
BRPI0012675B8 (2) 2021-05-25
HK1048248B (zh) 2005-04-22
JP2003505472A (ja) 2003-02-12
AR024907A1 (es) 2002-10-30
AU5843200A (en) 2001-02-13
CN1364086A (zh) 2002-08-14
BR0012675A (pt) 2002-04-09
NZ516535A (en) 2004-04-30
NO20020153L (no) 2002-03-11
CY1107932T1 (el) 2013-09-04
EP1206274B1 (en) 2007-05-30
HK1048248A1 (en) 2003-03-28
EE04838B1 (et) 2007-06-15
US7741276B2 (en) 2010-06-22
CA2380216A1 (en) 2001-02-01
CN1173736C (zh) 2004-11-03
HU228780B1 (en) 2013-05-28
DE60035049T2 (de) 2007-09-27
UA73745C2 (en) 2005-09-15
HUP0202107A3 (en) 2005-01-28

Similar Documents

Publication Publication Date Title
US7741276B2 (en) Use of interleukin-18 inhibitors to inhibit tumor metastasis
Smith et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF
Edwards III PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases
Armant et al. Regulation of cytokine production by soluble CD23: costimulation of interferon gamma secretion and triggering of tumor necrosis factor alpha release.
JP2018087244A (ja) 炎症性疾患および自己免疫疾患の処置の組成物および方法
JP2004536056A (ja) Ｒａｎｋアンタゴニストの療法使用
WO2006116185A2 (en) Methods for the treatment of multiple myeloma
Kanda et al. Transforming growth factor α protects against Fas-mediated liver apoptosis in mice
JPH0725785A (ja) インターロイキン−６の医薬組成物
KR101769122B1 (ko) 케모카인 발현 조절제
Ryffel et al. Correction of the TNF‐LTα‐Deficient Phenotype by Bone Marrow Transplantation
Passeri Interleukin-11: a new cytokine critical for osteoclast development
Berghen et al. P101 DOT1L inhibition increases dermal fibroblast proliferation but has no effects on in vitro or in vivo collagen deposition in models of fibrosis
Jiang Increased core temperature during febrile disease modulates cytokine expression, enhances host defense, and improves survival in bacterial infection
Piccoli et al. Hyporesponsiveness of Natural Killer Activity Induced in Vivo By Multiple Treatment with Maleic Acid Anhydride Divinyl Ether (MVE-2)
Armant et al. Regulation of Cytokine Production by Soluble CD23: Costimulation of Interferon 3'Secretion and Triggering of Tumor Necrosis Factor c~ Release
AU2002257303A1 (en) Therapeutic use of rank antagonists

Legal Events

Date Code Title Description
MK1K Patent expired